Compass Therapeutics, Inc.

CMPX Healthcare Biotechnology

Compass Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $850,000.00. In the quarter to June 2026, EPS grew 7.14% and free cash flow fell 26.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.86 0.04 −4.44%
Market cap
$161.5M
P/E
0.0×
Fwd P/E
−14.6×
Dividend yield
—
F-score
n/a
Altman Z
3.98
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
17.82 15.02 19.04 11.22
Net Debt/EBITDA
13.90 11.10 9.67 6.71
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.06) (0.08) (0.09) (0.08)
Book value per Share
1.24 1.25 1.00 0.89
Free Cash Flow
(10.86) (13.25) (17.35) (14.91)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates